News
PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company today announced that its majority-owned digital health subsidiary Veris Health (“Veris”) has
Agilent Announces the 2022 Darlene Solomon Award Presented to Grenoble Alpes University Hospital Scientist Dr. Federica Fiorini
Agilent Technologies Inc. (NYSE: A) today announced that the recipient of the 2022 Darlene Solomon Award is Federica Fiorini, Ph.D., a research associate studying metabolomics at the Institute of
PAVmed to Hold a Business Update Conference Call on March 29, 2022
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the companies will host a business update conference call on
Simulations Plus to Present at Oppenheimer Annual Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting
Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced
Lucid Diagnostics to Participate in the LSI USA ’22 Emerging Medtech Summit
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
Simulations Plus to Present at Raymond James Institutional Investors Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting
NanoString Technologies Releases Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the fourth quarter and year
FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the FDA has granted Breakthrough Device Designation for
FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the FDA has granted Breakthrough Device Designation for
Premier, Inc. to Participate in Upcoming Investor Conferences
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in the following investor
Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at
Acadia Healthcare Reports Fourth Quarter 2021 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2021.
Fourth Quarter Highlights
-
Revenue totaled $593.5
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study
NanoString to Webcast Presentation from the 42nd Annual Cowen Health Care Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a
Agilent to Participate at Cowen and Barclays Health Care Conferences
Agilent Technologies Inc. (NYSE: A) today announced that Bob McMahon, senior vice president and chief financial officer, will participate in Q&A sessions at the Cowen 42nd Annual Health Care
Agilent and University of Vermont Announce the Agilent Laboratory for Chemical Analysis (ALCA)
Agilent Technologies Inc. (NYSE: A) and the University of Vermont (UVM) today announced the establishment of the Agilent Laboratory for Chemical Analysis (ALCA). The facility will be a hub for
STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening
Agilent Technologies Inc. (NYSE: A) announced today that researchers from the QIMR Berghofer Medical Research Institute in Brisbane, Australia, collaborated with Agilent experts on a
LivaNova Reports Fourth-Quarter and Full-Year 2021 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021.
For the fourth quarter of
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care published form 20-F for the fiscal year 2021
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2021
Agilent Reports First-Quarter Fiscal Year 2022 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the first quarter ended Jan. 31, 2022, an increase of 8% compared to the first quarter of 2021 and up 9% on a core(1)
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care sets climate targets: Climate neutrality by 2040, CO2 emissions to fall 50% by 2030